Literature DB >> 25550083

Structural and sequential context of p53: A review of experimental and theoretical evidence.

Taniya Saha1, Rajiv K Kar2, Gaurisankar Sa3.   

Abstract

Approximately 27 million people are suffering from cancer that contains either an inactivating missense mutation of TP53 gene or partially abrogated p53 signaling pathway. Concerted action of folded and intrinsically disordered domains accounts for multi-faceted role of p53. The intricacy of dynamic p53 structure is believed to shed light on its cellular activity for developing new cancer therapies. In this review, insights into structural details of p53, diverse single point mutations affecting its core domain, thermodynamic understanding and therapeutic strategies for pharmacological rescue of p53 function has been illustrated. An effort has been made here to bridge the structural and sequential evidence of p53 from experimental to computational studies. First, we focused on the individual domains and the crucial protein-protein or DNA-protein contacts that determine conformation and dynamic behavior of p53. Next, the oncogenic mutations associated with cancer and its contribution to thermodynamic fluctuation has been discussed. Thus the emerging anti-cancer strategies include targeting of destabilized cancer mutants with selective inhibition of its negative regulators. Recent advances in development of small molecule inhibitors and peptides exploiting p53-MDM2 interaction has been included. In a nutshell, this review attempts to describe structural biology of p53 which provide new openings for structure-guided rescue.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Molecular dynamics simulation; Mutation; Small molecule inhibitor; Thermodynamic; p53

Mesh:

Substances:

Year:  2014        PMID: 25550083     DOI: 10.1016/j.pbiomolbio.2014.12.002

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  20 in total

Review 1.  Notch signaling and neuronal death in stroke.

Authors:  Thiruma V Arumugam; Sang-Ha Baik; Priyanka Balaganapathy; Christopher G Sobey; Mark P Mattson; Dong-Gyu Jo
Journal:  Prog Neurobiol       Date:  2018-03-21       Impact factor: 11.685

2.  N6-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation.

Authors:  Tianhe Zhao; Donglei Sun; Manyu Zhao; Yanhao Lai; Yuan Liu; Zunzhen Zhang
Journal:  Environ Pollut       Date:  2020-01-07       Impact factor: 8.071

3.  Investigating Conformational Dynamics and Allostery in the p53 DNA-Binding Domain Using Molecular Simulations.

Authors:  Elena Papaleo
Journal:  Methods Mol Biol       Date:  2021

4.  Somatic Mutations in TP53 Gene in Colombian Patients With Non-melanoma Skin Cancer.

Authors:  Luz Dary Gutiérrez-Castañeda; María Irene Cerezo-Cortés; John Nova
Journal:  Cancer Diagn Progn       Date:  2022-01-03

5.  Homologs of the Tumor Suppressor Protein p53: A Bioinformatics Study for Drug Design.

Authors:  Kelly M Thayer; Claudia Carcamo
Journal:  MOJ Proteom Bioinform       Date:  2020-02-05

Review 6.  Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways.

Authors:  Dariusz Stępiński
Journal:  Histochem Cell Biol       Date:  2016-05-03       Impact factor: 4.304

7.  Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors.

Authors:  Amy L Sherborne; Vincent Lavergne; Katharine Yu; Leah Lee; Philip R Davidson; Tali Mazor; Ivan V Smirnoff; Andrew E Horvai; Mignon Loh; Steven G DuBois; Robert E Goldsby; Joseph P Neglia; Sue Hammond; Leslie L Robison; Rosanna Wustrack; Joseph F Costello; Alice O Nakamura; Kevin M Shannon; Smita Bhatia; Jean L Nakamura
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

Review 8.  The Function of the Mutant p53-R175H in Cancer.

Authors:  Yen-Ting Chiang; Yi-Chung Chien; Yu-Heng Lin; Hui-Hsuan Wu; Dung-Fang Lee; Yung-Luen Yu
Journal:  Cancers (Basel)       Date:  2021-08-13       Impact factor: 6.639

9.  MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1.

Authors:  Yang Peng; Wen Dong; Tian-Xin Lin; Guang-Zheng Zhong; Bei Liao; Bo Wang; Peng Gu; Li Huang; Yun Xie; Fu-Ding Lu; Xu Chen; Wei-Bin Xie; Wang He; Shao-Xu Wu; Jian Huang
Journal:  Oncotarget       Date:  2015-06-30

Review 10.  Identification of inhibitors of biological interactions involving intrinsically disordered proteins.

Authors:  Daniela Marasco; Pasqualina Liana Scognamiglio
Journal:  Int J Mol Sci       Date:  2015-04-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.